TO FIND OUT MORE VISIT OUR EXHIBITION STALL OR WATCH DR McCLUNAN'S PRESENTATION AT WOC2020

iPortVR

 

The iPortVR is a vitreoretinal oculosubarachnoid glaucoma device (VOGD), inserted via the ab-interno (from the inside) pathway. The device creates a micro shunt communication between the ocular posterior chamber and the retrolaminar subarachnoid space.


The iPortVR is the first ever glaucoma device designed for use during vitreoretinal(VR) surgery, which is commonly associated with glaucoma. iValve technology built into the design makes the iPortVR compatible for use with all VR tamponading agents.

The iPortVR offers the highly effective, cost saving benefits of oculosubarachnoid shunting, while making use of ab-interno implantation to be fast, simple and minimally invasive to insert.


Pre-clinical testing of the iPortVR is currently underway. The Glaucoma treatment by Oculosubarachnoid Vitreoretinal Implant Device (GOVID) study is the iPortVR early feasibility study planned to kick off in 2021.

Glaucoma remains a leading cause of blindness worldwide, affecting over 70 million people

Contact

Dr Daemon McClunan, Founder
email: daemon@liqidmedical.com

mobile: +27 (0)84 604 7600

location: Cape Town, South Africa

© 2017 Copyright reserved. Online Solutions by CassandraGroenewald.com